A comparison of obstetrical outcomes and costs between misoprostol and dinoprostone for induction of labor |
| |
Authors: | Kunzier Nadia Bennett Hyein Park Joseph Cioffi Rose Calixte Anthony Vintzileos |
| |
Affiliation: | 1. Department of Obstetrics and Gynecology, Stony Brook University – Winthrop University Hospitals, Mineola, NY, USA and;2. Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, NY, USAnbennett@nyit.edu;4. Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, NY, USA |
| |
Abstract: | Objective: The objective of this study is to compare resource utilization (efficiency) and obstetrical/cost outcomes of single dose misoprostol versus dinoprostone for induction of labor (IOL) at term.Methods: Retrospective cohort of induced deliveries 37–41 weeks gestation presenting with a Bishop score?≤4 using single-dose-50?mcg vaginal misoprostol or 10?mg-dinoprostone vaginal-inserts. Dinoprostone patients were compared (5:1) with misoprostol patients. The primary outcome variable was length of L&D stay (proxy for resource utilization). Baseline characteristics, clinical outcomes, and costs were compared.Results: Three-hundred thirty-one patients were included, 276 received dinoprostone and 55 received misoprostol. The misoprostol group had statistically significant decreased time to active labor [median 8?h (1.6,24) versus 12(0.8,52)], time-to-delivery [median 11?h (4,31) versus 17(2.8,56)] and L&D stay [median 16?h (13,28) versus 24(18,30)]. Differences remained significant after adjustment for race, method of delivery, birth weight, gravidity/parity, gestational age, and BMI (adjusted p values?<0.001, <0.01, and?0.05, respectively). There were no statistical differences in Apgar scores, tachysystole rate, cesarean section rate, and composite maternal/neonatal morbidity. A policy of using misoprostol would result in annual cost savings of approximately $242 500 at our institution as compared with dinoprostone.Conclusion: Single-dose misoprostol is more efficient in IOL at term with respect to L&D utilization and cost and its use is not associated with increased adverse obstetrical outcomes. |
| |
Keywords: | Clinical outcomes cost analysis induction of labor prostaglandin term gestation |
|
|